Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Neuroprotection for Diabetic Retinopathy: a New Therapeutic Strategy

IP: Rafael Simó Canonge
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT14/00050
Duration: 13/05/2015 - 31/12/2015

Pendent de complimentar

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII14/00032
Duration: 01/02/2015 - 31/01/2018

Neuroprotección en la retinopatía diabética: una nueva estrategia terapéutica

IP: Rafael Simó Canonge
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 83900
Reference: BES-2013-064944
Duration: 07/01/2014 - 06/01/2018

Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary clinical and experimental approach

IP: -
Collaborators: Ignacio Ferreira González, José Antonio Barrabés Riu, Joan Montaner Villalonga, Immaculada Raurell Saborit, Joan López Hellin, Antonio González Fernández, Antonia Sambola Ayala, Joaquin Lopez Soriano, Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary c, Antonio Rodríguez Sinovas, Rafael Simó Canonge, Francesc Moreso Mateos, Cristina Hernández Pascual, Anna Penalba Morenilla, Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary c, Neus Bellera Gotarda, Natalia Ramos Terrades, Andreea Ciudin Mihai, Maria Mar Hernandez Guillamon, Meritxell Ibernon Vilaró, Ignasi Barba Vert, Jordi Bañeras Rius, Bruno García del Blanco, Daniel Serón Micas, María Eugenia Espinel Garuz, Marisol Ruiz Meana, Maria Pilar Delgado Martínez, Irina Betsabe Torres Rodriguez, Javier Inserte Igual, Anna Rosell Novel, Olga Simó Servat, Joan Genescà Ferrer, Mònica Pons Delgado, M Antonieta Azancot Rivero, Maria Nazarena Pizzi, M Antonieta Azancot Rivero
Funding agency: Instituto de Salud Carlos III
Funding: 825000
Reference: PIE13/00027
Duration: 01/01/2014 - 30/06/2018

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Jordi Lozano Torres

Jordi Lozano Torres

Senior researcher
Cardiovascular Diseases
Read more
Isabel Ruiz Camps

Isabel Ruiz Camps

Infectious Diseases
Read more
Pau  Rello Sabaté

Pau Rello Sabaté

Predoctoral researcher
Cardiovascular Diseases
Read more
Jorge Leno Colorado

Jorge Leno Colorado

Research technician
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.